151 related articles for article (PubMed ID: 19490202)
1. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors.
Schernthaner G
Int J Clin Pract; 2009 Jun; 63(6):912-29. PubMed ID: 19490202
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic effects of thiazolidinediones.
Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
[TBL] [Abstract][Full Text] [Related]
3. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
5. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular manifestations of insulin resistance.
Chahwala V; Arora R
Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
[TBL] [Abstract][Full Text] [Related]
7. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
8. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
Seufert J
Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
[TBL] [Abstract][Full Text] [Related]
9. Prevention of coronary heart disease in type 2 diabetes.
Mykkänen L
Int J Clin Pract Suppl; 2000 Oct; (113):40-5. PubMed ID: 11965831
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone: potential beneficial impact on cardiovascular disease.
Viberti GC
Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
[TBL] [Abstract][Full Text] [Related]
11. [Challenge in diabetes therapy: effects of glitazones beyond blood glucose control].
Schernthaner G; Forst T; Gulba D; Haberbosch W; Hanefeld M; Linss G; März W; Mehnert H; Rosak C; Schnell O; Seufert J; Tschöpe D; Erdmann E
Dtsch Med Wochenschr; 2009 Apr; 134(18):949-54. PubMed ID: 19384816
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
14. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of the thiazolidinediones.
Qayyum R; Schulman P
Diabetes Metab Res Rev; 2006; 22(2):88-97. PubMed ID: 16184618
[TBL] [Abstract][Full Text] [Related]
17. Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
Fisher M
Int J Clin Pract; 2009 Sep; 63(9):1354-68. PubMed ID: 19691621
[TBL] [Abstract][Full Text] [Related]
18. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Mazzone T
Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
[TBL] [Abstract][Full Text] [Related]
19. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
Barac A; Campia U; Matuskey LA; Lu L; Panza JA
Am J Cardiol; 2008 Apr; 101(7):980-5. PubMed ID: 18359318
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Roberts AW; Thomas A; Rees A; Evans M
Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
